Analyst Expectations For Ventas's Future
6 analysts have expressed a variety of opinions on Ventas (NYSE:VTR) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 4 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 3 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $92.83, along with a high estimate of $96.00 and a low estimate of $90.00. Surpassing the previous average price target of $86.00, the current average has increased by 7.94%.
Analyzing Analyst Ratings: A Detailed Breakdown
A clear picture of Ventas's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Vikram Malhorta | Mizuho | Raises | Outperform | $94.00 | $87.00 |
| Nicholas Yulico | Scotiabank | Raises | Sector Perform | $93.00 | $80.00 |
| Nick Joseph | Citigroup | Raises | Buy | $96.00 | $88.00 |
| Michael Carroll | RBC Capital | Raises | Outperform | $91.00 | $83.00 |
| Todd M. Thomas | Keybanc | Raises | Overweight | $90.00 | $85.00 |
| Richard Anderson | Cantor Fitzgerald | Maintains | Overweight | $93.00 | $93.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ventas. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ventas compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Ventas's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Ventas's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Ventas analyst ratings.
Delving into Ventas's Background
Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
Breaking Down Ventas's Financial Performance
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Ventas's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2025, the company achieved a revenue growth rate of approximately 21.67%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Ventas's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 4.48%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Ventas's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.56%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.26%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Ventas's debt-to-equity ratio is below the industry average at 1.06, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Significance of Analyst Ratings Explained
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.